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Background: Sporadic Creutzfeldt-Jakob disease is classified according to the genotype at polymorphic codon 129
(M or V) of the prion protein (PrP) gene and the type (1 or 2) of abnormal isoform of PrP (PrPSc) in the brain. The
most complicated entity in the current classification system is MV2, since it shows wide phenotypic variations, i.e.,
MV2 cortical form (MV2C), MV2 with kuru plaques (MV2K), or a mixed form (MV2K + C). To resolve their complicated
pathogenesis, we performed a comprehensive analysis of the three MV2 subgroups based on histopathological,
molecular, and transmission properties.
Results: In histopathological and molecular analyses, MV2C showed close similarity to MM2 cortical form (MM2C)
and could be easily discriminated from the other MV2 subgroups. By contrast, MV2K and MV2K + C showed the
same molecular type and the same transmission type, and the sole difference between MV2K and MV2K + C was
the presence of cortical pathology characteristic of MV2C/MM2C. The remarkable molecular feature of MV2K or
MV2K + C was a mixture of type 2 PrPSc and intermediate type PrPSc, which shows intermediate electrophoretic
mobility between types 1 and 2 PrPSc. Modeling experiments using PrP-humanized mice indicated that MV2K
contains a mixture of intermediate type PrPSc with the 129M genotype (Mi PrPSc) and type 2 PrPSc with the 129V
genotype (V2 PrPSc) that originated from V2 PrPSc, whereas MV2C + K may also contain type 2 PrPSc with the
129M genotype and cortical pathology (M2C PrPSc) that lacks infectivity to the PrP-humanized mice in addition to
Mi and V2 PrPSc.
Conclusions: Taken together, the present study suggests that the phenotypic heterogeneity of MV2 stems from
their different PrPSc origin(s).
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Creutzfeldt-Jakob disease (CJD) is a lethal transmissible
neurodegenerative disease caused by an abnormal iso-
form of prion protein (PrPSc), which is converted from
the normal cellular isoform (PrPC) [1]. There is a poly-
morphism (methionine, M; or valine, V) at codon 129
of the prion protein (PrP) gene. Parchi and colleagues
reported that the codon 129 genotype (M/M, M/V, or
V/V) and the type (type 1 or type 2) of PrPSc in the* Correspondence: kitamoto@med.tohoku.ac.jp
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stated.brain are major determinants of the clinicopathologi-
cal phenotypes of sporadic CJD (sCJD) [2-5]. Type 1
and type 2 PrPSc are distinguishable according to the
size of the proteinase K (PK)-resistant core of PrPSc (21
and 19 kDa, respectively), reflecting differences in the
PK-cleavage site (at residues 82 and 97, respectively)
[6]. According to this molecular typing system, sCJD
is classified into six subgroups (MM1, MM2, MV1,
MV2, VV1, or VV2). In addition, MM2 can be divided
into two subgroups based on histopathological criteria
(MM2C, cortical form showing a predominant cortical
pathology; or MM2T, thalamic form showing charac-
teristic atrophy of thalamic and inferior olivary nuclei)ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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PrPSc typing, and histotyping, has been widely used com-
pared with an alternative classification system proposed
by others [7,8].
Among the seven sCJD subgroups, the most compli-
cated entity is MV2, which accounts for 11% of total
sCJD [5]. Since MV2 shows wide phenotypic variations,
Parchi and colleagues have proposed dividing this het-
erogeneous entity based on histopathological criteria
(MV2C showing a predominant cortical pathology or
MV2K showing kuru type PrP amyloid plaques) [9].
Moreover, the co-occurrence of these histotypes in the
same brain (denoted as MV2K + C) has also been re-
ported [9]. MV2K is the most common subgroup in MV2
(8% of total sCJD cases), whereas MV2C is very rare
(< 0.5%) [5,9]. MV2K + C is relatively common but some-
times misdiagnosed as MV2K even by experts of CJD
surveillance centers [10]. Besides these complicated his-
totypes, type 2 PrPSc in certain MV2 cases shows atypical
features, i.e., wide, heterogeneous fragments that migrate
at approximately 20 to 19 kDa and are sometimes visible
as doublets [4,11,12]. The atypical type 2 PrPSc has been
reported in MV2K and MV2K + C but not in MV2C. The
molecular mechanisms of the atypical type 2 PrPSc for-
mation remain elusive. In addition, the atypical type 2
PrPSc has not been recapitulated in an experimental
transmission of MV2K to PrP-humanized mice carrying
the 129M/V genotype [13].
To characterize the MV2 subgroups in detail and to
resolve their complicated pathogenesis, we performed a
comprehensive analysis of the MV2 subgroups based on
histopathological, molecular and transmission properties.Methods
Patients
CJD cases included in this study were patients with clinic-
ally, genetically and histopathologically proven sCJD. Brain
tissues were obtained at autopsy from CJD patients after
receiving informed consent for research use. The diagnosis
of sCJD, histotype, and PrPSc type were confirmed by PrP
immunohistochemistry and western blot analysis [14,15].
The genotype and the absence of mutations in the open
reading frame of the PrP gene were determined by se-
quence analysis as described [16]. According to Parchi’s
classification [4,5], these sCJD cases were classified as fol-
lows: MM1, 1 case; MM2C, 1 case; VV2, 1 case; MV2C, 1
case; MV2K, 1 case; and MV2K+C, 1 case. These patients
showed the typical phenotypes of each sCJD subgroup
in the clinicopathological and biochemical examinations.
Ethical approval for these studies was obtained from the
Ethical Committee of Tohoku University Graduate School
of Medicine. All experiments carried out on humans were
in compliance with the Helsinki Declaration.Transmission experiments
Brain homogenates (10%) were prepared as described [17].
Intracerebral transmission to PrP-humanized mice was
performed using 20 μl of the homogenates [15]. The pro-
duction of the knock-in mice expressing human PrP with
the 129M/M genotype (Ki-Hu129M/M), Ki-Hu129M/V,
and Ki-Hu129V/V has been reported [17,18]. The expres-
sion levels of human PrP in the brains of these knock-in
mice were identical to the level observed in wild-type
mouse. The inoculated mice were sacrificed after the onset
of disease or at death. One hemisphere of the brain was
fixed in 10% buffered formalin for immunohistochemistry,
and the other hemisphere was immediately frozen for
western blotting. Ethical approval for these experiments
using mice was obtained from Animal Care and Use Com-
mittee of Tohoku University Graduate School of Medicine.Immunohistochemistry
Formalin-fixed brain tissues were treated with formic
acid (99% for human tissues or 60% for mouse tissues)
for 1 hour to inactivate the infectivity, and embedded in
paraffin. Tissue sections were pretreated by hydrolytic
autoclaving before PrP immunohistochemistry [14]. The
anti-PrP monoclonal antibodies 3F4 [19] and #71 [20,21]
were used as the primary antibodies for human sections,
and anti-PrP antiserum PrP-N [22] was used as the pri-
mary antibody for mouse sections. Goat-anti-mouse
immunoglobulin polyclonal antibody labelled with the
peroxidase-conjugated dextran polymer, EnVision + (Dako)
and anti-rabbit EnVision + were used as the secondary
antibodies. For the quantification of PrP plaques in the pa-
tient brains, at least six representative digital microscopy
images were taken at 10× magnification from each brain
region and analyzed using ImageJ software (rsb.info.nih.
gov/ij). The number of PrP plaques was manually counted,
and the mean plaque density in each brain region was
calculated.Western blotting
PrPSc was extracted from human or mouse brains with
collagenase treatment as described [23]. For deglyco-
sylation of PrPSc, samples were digested with PNGaseF
(New England Biolabs) as reported [24]. Protein samples
were subjected to SDS-PAGE using 15% Tris-glycine long
gels of 15 cm length and western blotting [18]. Type 1
PrPSc- and type 2 PrPSc-specific polyclonal antibodies
(designated as Tohoku 1 (T1) and Tohoku 2 (T2), re-
spectively [25]) and the 3F4 antibody were used as the
primary antibodies. Anti-rabbit EnVision + and anti-mouse
EnVision + were used as the secondary antibodies. The sig-
nal intensities of the western blots were quantified with
Quantity One software using an imaging device VersaDoc
5000 (Bio-Rad Laboratories).
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Incubation times and the signal intensities of PrPSc bands
are expressed as mean ± SEM.
Results
Histotyping and molecular typing of MV2.
At first, we performed histopathological analysis of the
three subgroups of MV2 (MV2K, MV2K + C, and MV2C;
Parchi’s classification [4,5] is used in this paper). MV2K
showed unicentric PrP amyloid plaques, kuru plaques,
throughout the cerebral grey matter and the cerebel-
lum as reported previously (Figure 1a, Additional file 1:
Figure S1a, e) [4]. These plaques were prominent es-
pecially in the granular cell layer of the cerebellum.
MV2K +C showed large confluent vacuoles and periva-
cuolar PrP deposition in the cerebral cortices besides
scattered kuru plaques as reported (Figure 1b, Additional
file 1: Figure S1b, f ) [4]. The large confluent vacuoles
and perivacuolar PrP deposition in the cerebral cortices
were characteristics of MV2C and MM2C (Figure 1c, d;
Additional file 1: Figure S1c, d, g, h) [4,9]. The cerebellum
of MV2K +C contained numerous PrP plaques in the
granular cell layer. Thus, MV2K +C showed mixed histo-
types, i.e., a mixture of the MV2C/MM2C phenotype and
MV2K phenotype. PrP plaques were absent in the brain of
MV2C even in the granular cell layer of the cerebellum. In-
stead, MV2C and MM2C showed focal amorphous patchy
PrP deposition in the molecular layer of the cerebellum as
reported [5]. Thus, the three MV2 subgroups exhibited
clearly different histotypes.
Next we performed western blot analysis of PrPSc in
the brains of three MV2 subgroups using PrPSc type-
specific antibodies and a conventional anti-PrP antibody
3F4 that detects all PrPSc types. Type 1 PrPSc-specific
antibody Tohoku 1 (T1) recognizes epitopes between resi-
dues 82 and 96 that are retained in type 1 PrPSc but not in
type 2 PrPSc after PK-digestion. In addition, the epitopes
for the T1 antibody are also retained in the intermediate
type PrPSc showing intermediate electrophoretic mobility
between types 1 and 2 PrPSc, which is observed in a part of
dura mater-graft associated CJD [25]. Type 2 PrPSc-specific
antibody Tohoku 2 (T2) specifically detects the N-terminal
PK-cleavage site of type 2 PrPSc (at residue 97) [25]. In
the conventional western blot analysis using the anti-PrP
antibody 3F4, MV2K and MV2K +C had heterogeneous
unglycosylated bands located at 20 kDa to 19 kDa as re-
ported (Figure 1e) [4]. Since the upper unglycosylated band
migrated faster compared with type 1 PrPSc from MM1,
these heterogeneous bands were different from the co-
occurrence of types 1 (21 kDa) and 2 (19 kDa) PrPSc. In
contrast, MV2C and MM2C had only type 2 PrPSc located
at 19 kDa. In the western blot analysis using the PrPSc
type-specific antibodies, MV2K and MV2K +C had large
amounts of T1-reactive PrPSc in addition to T2-reactivePrPSc (Figure 1f). The amounts of T1-reactive PrPSc in the
MV2K cerebrum were relatively low compared with the
cerebellum, suggesting regional variability in the ratio of
the amounts of T1-reactive PrPSc to the amounts of T2-
reactive PrPSc. The low amounts of T1-reactive PrPSc in
the MV2K cerebrum accounted for the absence of the 20
kDa (upper) unglycosylated band in the western blot using
the 3F4 antibody, since conventional western blot ana-
lysis using antibodies that react with all PrPSc types can-
not detect a coexisting minority component [26]. In
addition, the T2-reactive PrPSc in the cerebellum of MV2K
or MV2K +C consisted of ladder-like multiple fragments,
which were quite different from the T2-reactive PrPSc in
the cerebrum. Thus, MV2K and MV2K +C showed similar
molecular properties in the western blot analysis using the
PrPSc type-specific antibodies. By contrast, MV2C and
MM2C had predominant T2-reactive PrPSc with only
trace amounts of T1-reactive PrPSc as reported [26,27].
MM1 had predominant T1-reactive PrPSc with trace
amounts of T2-reactive PrPSc as reported [28]. Taken to-
gether, MV2C was clearly different from the other MV2
subgroups in the molecular typing as well, whereas MV2K
and MV2K +C could not be distinguished by molecular
typing even with the PrPSc type-specific antibodies.
Transmission typing of MV2
To characterize further the MV2 subgroups, we then per-
formed transmission experiments using PrP-humanized
mice. These knock-in mice (Ki-Hu129M/M, Ki-Hu129M/
V, or Ki-Hu129V/V) express human PrP with either the
129M/M, M/V, or V/V genotype at the same level. Since
the expression level of PrP affects the susceptibility to
PrPSc infection regardless of the PrP genotype, these
knock-in mice have an advantage over transgenic mice
for evaluating the susceptibility among the genotypes
[18]. After intracerebral challenge with the MV2K brain
material, Ki-Hu129M/M and Ki-Hu129M/V showed
much longer incubation times compared with those of
Ki-Hu129V/V (Figure 2). Inoculation of the MV2K + C
brain material resulted in the same transmission patterns
as those of MV2K. Furthermore, the histopathological
phenotypes of MV2K and those of MV2K + C in the in-
oculated mice were also indistinguishable (Figure 3a, b).
Ki-Hu129M/M showed variously sized, round, plaque-
type PrP deposits throughout the cerebral grey matter,
white matter, striatum, and thalamus. Ki-Hu129M/V had
fewer PrP plaques compared with the Ki-Hu129M/M. In
Ki-Hu129V/V, PrP plaques were restricted to within the
white matter. Large confluent vacuoles or perivacuolar
PrP deposition, which are characteristics of MV2C/
MM2C, were absent in the MV2K + C-inoculated mice.
The conventional western blot analysis of PrPSc in the
brains from MV2K- or MV2K + C-inoculated mice using
the 3F4 antibody revealed that Ki-Hu129M/M produced
Figure 1 (See legend on next page.)
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Figure 1 Histotyping and molecular typing of the MV2 subgroups. (a-d) Histopathological features of MV2K (a), MV2K + C (b), MV2C (c), or
MM2C (d) (hematoxylin and eosin stain and immunohistochemistry for PrP). Higher magnification of kuru plaques (arrows) is shown in the insets. M,
molecular layer; G, granular cell layer. Scale bar: 100 μm. (e) Western blot analysis of PrPSc in the brains using anti-PrP antibody 3F4 and PrPSc-type
specific antibodies T1 or T2. Protein samples were prepared from the frontal cortices. In addition, cerebellar cortices of MV2K or MV2K + C were also
examined. (f) The mean signal intensities of 3F4-, T1-, or T2-reactive PrPSc. To compare the amounts of the T1- or T2-reactive PrPSc among the
patients, the signal intensities of the T1- or T2-reactive PrPSc were normalized by those of the 3F4-reactive PrPSc. The mean signal intensities of
MM1 were assigned as 100 /mm2 in each experiment using 3F4 or T1 antibody, and those of MM2C were assigned as 100 /mm2 in each experiment
using T2 antibody. All experiments were repeated independently at least three times.
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type 2 PrPSc, i.e., a mixture of the 20 kDa PrPSc and
type 2 PrPSc, and Ki-Hu129V/V produced type 2 PrPSc
(Figure 3c). Western blot analysis using the PrPSc type-
specific antibodies revealed that the amounts of T1-
reactive PrPSc gradually decreased from Ki-Hu129M/M
to Ki-Hu129M/V to Ki-Hu129V/V, while the amounts of
T2-reactive PrPSc gradually increased from Ki-Hu129M/
M to Ki-Hu129M/V to Ki-Hu129V/V (Figure 3d). Thus,
MV2K and MV2K + C could also not be distinguished by
transmission typing.
Modelling of MV2
To resolve the complicated pathogenesis of MV2, we hy-
pothesized that MV2K might have originated from type
2 PrPSc with the 129V genotype (denoted as V2 PrPSc)Figure 2 Transmission of sCJD to PrP-humanized mice. The mean in
Ki-Hu129V/V were 638 ± 57 days (number of mice positive for PrP accumulatio
713 ± 0 days (3/4), and 329 ± 3 days (4/4), respectively. The mean incubation tim
were 600 ± 22 days (6/6), 638 ± 11 days (7/7), and 332 ± 15 days (4/4), respe
Ki-Hu129M/V, and Ki-Hu129V/V were 633 ± 49 days (6/6), 788 ± 30 days (4/4
MM1-inoculated Ki-Hu129M/M, Ki-Hu129M/V, and Ki-Hu129V/V were 467 ± 2
The details of the transmission experiments of VV2 or MM1 using Ki-Hu129and might contain V2 PrPSc and the intermediate type
PrPSc with the 129M genotype (denoted as Mi PrPSc),
since we previously found that PrPC with the 129M
genotype in Ki-Hu129M/M converted into Mi PrPSc
after challenge with VV2 brain material containing V2
PrPSc. These Mi PrPSc showed striking similarity to the
20 kDa PrPSc in MV2K or MV2K + C [25,29,31]. Mean-
while, MV2K + C might also contain type 2 PrPSc with
the 129M genotype and cortical pathology (denoted as
M2C PrPSc) in addition to Mi and V2 PrPSc, since
MV2C showed close similarity to MM2C that contains
M2C PrPSc, as described above.
To test this hypothesis, we first performed intracere-
bral inoculation of a VV2 brain material containing V2
PrPSc into Ki-Hu129M/V, as an experimental model of
MV2K. The VV2-inoculated Ki-Hu129M/V developedcubation times of MV2K-inoculated Ki-Hu129M/M, Ki-Hu129M/V, and
n in immunohistochemical analysis/number of inoculated mice = 4/4),
es of MV2K + C-inoculated Ki-Hu129M/M, Ki-Hu129M/V, and Ki-Hu129V/V
ctively. The mean incubation times of VV2-inoculated Ki-Hu129M/M,
), and 302 ± 9 days (7/7), respectively. The mean incubation times of
4 days (8/8), 490 ± 26 days (5/5), and 774 ± 32 days (6/6), respectively.
M/M and Ki-Hu129V/V have been reported previously [25,29].
Figure 3 (See legend on next page.)
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Figure 3 Transmission properties of MV2K and MV2K + C. (a) Immunohistochemical analysis of PrP in the brains of MV2K- or MV2K + C-inoculated
mice. Ki-Hu129M/V showed fewer PrP plaques (arrows) compared with Ki-Hu129M/M. G, grey matter; W, white matter. Scale bar: 100 μm. (b) Summary
of the distribution of PrP plaques in the brains of MV2K- or MV2K + C-inoculated mice. The distribution of PrP plaques (black dots) was plotted on the
illustrations showing the level of bregma −1.79 mm from “The Mouse Brain, 4th edition” [30]. (c) Western blot analysis of PrPSc in the brains using
anti-PrP antibody 3F4 and PrPSc-type specific antibodies T1 or T2. (d) The mean signal intensities of 3F4-, T1-, or T2-reactive PrPSc. To compare the
amounts of the T1- or T2-reactive PrPSc among the mice, the signal intensities of the T1- or T2-reactive PrPSc were normalized by those of the
3F4-reactive PrPSc. The mean signal intensities of MM1-inoculated Ki-Hu129M/M were assigned as 100 /mm2 in each experiment using 3F4 or T1
antibody, and those of MV2K + C-inoculated Ki-Hu129V/V were assigned as 100 /mm2 in each experiment using T2 antibody. All experiments were
repeated independently at least three times.
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mice showed PrP plaques in the cerebral grey matter,
white matter, striatum, and thalamus (Figure 4a, b). As
reported previously [29], VV2-inoculated Ki-Hu129M/M
had more PrP plaques throughout the brain, whereas
VV2-inoculated Ki-Hu129V/V showed restricted plaque
distribution within the white matter. Western blot ana-
lysis of PrPSc in the brain revealed that VV2-inoculated
Ki-Hu129M/V produced a mixture of the intermediate
type PrPSc and type 2 PrPSc similar to the atypical type 2
PrPSc in the MV2K or MV2K + C patients (Figure 4c-e).
VV2-inoculated Ki-Hu129M/M produced the intermediate
type PrPSc with the 129M genotype (Mi PrPSc), whereas
VV2-inoculated Ki-Hu129V/V produced type 2 PrPSc with
the 129V genotype (V2 PrPSc) as reported [25,29]. These
results indicated that V2 PrPSc generated both Mi and V2
PrPSc in animals with the 129M/V genotype.
Next we performed intracerebral inoculation of MM2C
brain material containing M2C PrPSc into the PrP-
humanized mice to gain insight into the reason why
MV2K + C (containing M2C, Mi, and V2 PrPSc) and
MV2K (containing Mi and V2 PrPSc) could not be distin-
guished by transmission typing. As expected, none of the
MM2C-inoculated mice had developed disease by the end
of their life span. An accumulation of PrPSc was absent in
the brains of the MM2C-inoculated mice (Additional file 2:
Figure S2). Thus, M2C PrPSc lacked infectivity to the PrP-
humanized mice.
Discussion
We performed a comprehensive analysis of the MV2
subgroups, i.e., MV2C, MV2K, and MV2K + C, and re-
solved their complicated pathogenesis. MV2C showed
close similarity to MM2C in the histopathological and
molecular analyses and could be easily discriminated
from the other MV2 subgroups. By contrast, MV2K and
MV2K +C showed the same molecular type and the same
transmission type. The remarkable molecular feature of
MV2K or MV2K +C was a mixture of the intermediate
type PrPSc and type 2 PrPSc. To model MV2K, we inocu-
lated VV2 brain material containing V2 PrPSc into the PrP-
humanized mice with the 129M/V genotype. These mice
showed widespread PrP plaques and the accumulation ofa mixture of the intermediate type PrPSc with the 129M
genotype (Mi PrPSc) and V2 PrPSc in the brain. These re-
sults suggest that MV2K contains Mi and V2 PrPSc that
originated from V2 PrPSc. In addition, we also inoculated
MM2C brain material containing M2C PrPSc into the PrP-
humanized mice to gain insight into the reason why
MV2K and MV2K +C could not be distinguished by trans-
mission typing. These transmission experiments revealed
that M2C PrPSc lacked infectivity to the PrP-humanized
mice. Therefore, the present data lead us to surmise that
MV2K +C may also contain M2C PrPSc lacking infectivity
to the PrP-humanized mice in addition to Mi and V2
PrPSc. Further study will be needed to verify that MV2C
and MM2C are identical in transmission typing as well as
histotyping and molecular typing. To grasp the whole pic-
ture of the phenotypic variability and PrPSc strain diversity
in the MV2 subgroups, a transmission study of MV2C is in
progress using the PrP-humanized mice.
The present study solves the mystery of the atypical
type 2 PrPSc in the MV2 subgroups. This heterogeneous
PrPSc consists of a mixture of the intermediate type PrPSc
and type 2 PrPSc, denoted as types i + 2. Differentiation of
the intermediate type PrPSc and type 2 PrPSc is difficult
with conventional western blot analysis and requires strict
conditions for PK-digestion and high resolution gel electro-
phoresis systems, e.g., 10-20% gradient Tris-glycine long
gels or Bis-tris long gels (Figure 4e) [11]. However, they
could be easily distinguished by the PrPSc type-specific
antibodies in the present study. Moreover, the co-
occurrence of the intermediate type PrPSc and type 2
PrPSc was recapitulated in the animal model for the first
time. Parchi and colleagues once proposed to designate
the atypical type 2 as type 2+20kDa [12], but they have
never used this nomenclature thereafter. To characterize
MV2 cases more adequately, we propose refined nomen-
clature as follows: MV2C, MVi + 2, or MVi + 2C (Table 1).
The present study suggests that pure type 2 PrPSc in
MV2C and the mixture of the intermediate type PrPSc
and type 2 PrPSc in MVi + 2 or MVi + 2C are different
and should be considered as distinct entities. In fact, Mi
PrPSc is always accompanied by kuru plaques in MVi + 2,
MVi + 2C, or dura mater graft-associated CJD with kuru
plaques (p-dCJD) [29,32], suggesting that Mi PrPSc is a
Figure 4 Modelling of MV2K. (a) Immunohistochemical analysis of PrP in the brains of VV2-inoculated PrP-humanized mice. G, grey matter; W,
white matter. Scale bar: 100 μm. (b) Summary of the distribution of PrP plaques in the brains of VV2-inoculated mice. The distribution of PrP pla-
ques (black dots) was plotted on the illustrations showing the level of bregma −1.79 mm from “The Mouse Brain, 4th edition” [30]. (c) Western
blot analysis of PrPSc in the brains using the anti-PrP antibody 3F4 and the PrPSc-type specific antibodies T1 or T2. (d) The mean signal intensities
of 3F4-, T1-, or T2-reactive PrPSc. To compare the amounts of the T1- or T2-reactive PrPSc among the mice, the signal intensities of the T1- or T2-
reactive PrPSc were normalized by those of the 3F4-reactive PrPSc. The mean signal intensities of MM1-inoculated Ki-Hu129M/M were assigned as
100 /mm2 in each experiment using the 3F4 or T1 antibody, and those of VV2-inoculated Ki-Hu129V/V were assigned as 100 /mm2 in each experi-
ment using the T2 antibody. All experiments were repeated independently at least three times. (e) Western blot analysis of deglycosylated PrPSc
using the 3F4 antibody. Ki-Hu129M/M produced the intermediate type PrPSc located at 20 kDa, Ki-Hu129V/V produced type 2 PrPSc located at 19
kDa, and Ki-Hu129M/V produced a mixture of these PrPSc bands.
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with the neuropathological phenotype. The amounts of
Mi PrPSc might vary among brain regions, as shown in
the western blot analysis of the MVi + 2 brain in the
present study. Unfortunately, we could not test this pos-
sibility in detail because additional brain materials were
not available. However, in the histopathological analysis,
the abundance of kuru plaques varied among brain
regions in the MVi + 2 or MVi + 2C patient (Additional
file 1: Figure S1). The prominent kuru plaque formation in
the cerebellum of MVi + 2 or MVi + 2C may indicate that
histopathological and molecular analyses of the cerebellum
would be useful to detect Mi PrPSc and kuru plaques,
which are two phenotypic hallmarks of MVi + 2 or MVi +
2C. Meanwhile, even in our comprehensive analysis, the
sole difference between MVi + 2 and MVi + 2C was thepresence of MV2C/MM2C pathology. Since MVi + 2C
cases with the very focal MV2C/MM2C pathology can be
misdiagnosed as MVi + 2 [10], further study will be needed
to assess whether MVi + 2 and MVi + 2C are distinguish-
able in their clinical features. Although we believe that the
refined nomenclature proposed here would contribute
to clarifying the complicated issues around the MV2 sub-
groups, the number of MV2 cases included in the present
study was very limited because MV2C, MVi + 2, and
MVi + 2C are rare in Japan compared with Western coun-
tries, reflecting the very low prevalence of the 129M/V
genotype in the healthy population [33]. We analyzed a
total of 232 cases with sCJD and found only 5 cases with
MVi + 2, 2 cases with MV2C (one of the patients carried
the M232R mutation on the 129M allele), and 1 case with
MVi + 2C. Although typical cases of each subgroup were






















MM1 1 M1CJD MM1 MM 1 S M1 M1 M1
MM2C 2 M2CJD MM2C MM 2 C ― M2C M2C
MV2C 2 N.D.e MV2C MV 2 C N.D.f M2C M2C
MV2K 2 V2CJD MVi + 2 MV i + 2g K V2 V2 Mi + V2
VV2 2 V2CJD VV2 VV 2 P V2 V2 V2
Mixed
phenotype
MV2K + C 2 N.D. MVi + 2C MV i + 2 K + C V2 M2C + V2 M2C+Mi + V2
aProposed nomenclature for the classification of sCJD subgroups analyzed in this study.
bAccording to Parchi et al., 1999 [4]; and Parchi et al., 2011 [5].
cAccording to Bishop et al., 2010 [13].
dS, synaptic; C, cortical form; K, kuru plaques; P, plaque-like.
eN.D., not done.
fTransmission experiment is in progress.
gMixture of the intermediate type and type 2 PrPSc.
Kobayashi et al. Acta Neuropathologica Communications 2013, 1:74 Page 9 of 11
http://www.actaneurocomms.org/content/1/1/74selected for the present study, we cannot exclude the possi-
bility of phenotypic variation within each subgroup. There-
fore, more extensive analyses of MV2 cases using PrPSc
type-specific antibodies and transmission studies including
additional MV2 cases are essential to validate the present
findings. Of note, although several type 1 PrPSc-specific
antibodies have been reported [25-27], the amounts of de-
tectable Mi PrPSc may differ among antibodies depending
on their epitopes, since the epitopes located near the N-
terminal PK-cleavage site of type 1 PrPSc can be lacking in
Mi PrPSc [25].
The generation of multiple PrPSc strains in heterozy-
gotes of the PrP genotypes can result in a long incubation
period due to interference among coexisting heterologous
PrPSc, designated as heterozygous inhibition [34,35]. In the
present study, V2 PrPSc-inoculated Ki-Hu129M/V pro-
duced Mi and V2 PrPSc and showed longer incubation
times compared with those of Ki-Hu129M/M despite its
expression of PrPC with the 129V genotype, which is an
optimal substrate for V2 PrPSc. Therefore, the long clinical
course of MVi + 2 or MVi + 2C [5] may also be due to het-
erozygous inhibition among the coexisting Mi and V2 (and
M2C) PrPSc.
Despite the coexistence of Mi and V2 PrPSc, MVi + 2
showed the same transmission properties as those of VV2
containing V2 PrPSc alone, as reported [13]. This result is
consistent with our previous findings that Mi PrPSc was
originated from V2 PrPSc and showed the same transmis-
sion properties as those of the parental V2 PrPSc [25].
Meanwhile, MVi + 2C containing M2C, Mi, and V2 PrPSc
also showed the same transmission properties as those
of VV2, since M2C PrPSc lacked infectivity to the PrP-
humanized mice and did not affect the transmission prop-
erties of the coexisting Mi and V2 PrPSc. Thus, the trans-
mission type does not reflect all existing PrPSc strains iftheir origins are identical or if they lack infectivity to ex-
perimental animals. Nevertheless, transmission typing will
remain indispensable for the risk assessment of PrPSc in-
fection among the PrP genotypes.
It remains unclear why M2C PrPSc lacked infectivity to
the PrP-humanized mice despite the fact that they could
propagate in the MM2C/MV2C patient brain. Although
there was no evidence of successful transmission in the
present study, very low infectivity of M2C PrPSc was re-
ported in a transmission study using other PrP-humanized
knock-in mouse lines [13]. The disease duration of MM2C/
MV2C patients is the longest among sCJD subgroups [5],
suggesting slow propagation of M2C PrPSc. Therefore,
M2C PrPSc may replicate less efficiently and take a longer
time to propagate compared with the other PrPSc strains.
Dura mater graft-associated CJD with kuru plaques
(p-dCJD) might be caused by infection of V2 PrPSc and/or
Mi PrPSc to individuals with the 129M/M genotype. We
reported previously that transmission of VV2 to animals
with the 129M/M genotype caused p-dCJD like phenotype,
i.e., widespread PrP plaques and an accumulation of Mi
PrPSc, and that the transmission properties of p-dCJD were
identical to those of VV2 [29]. It has been reported that
the transmission properties of MVi + 2 were the same as
those of VV2 [13,36]. In the present study, the transmis-
sion properties of MVi + 2C were also identical to those of
VV2, and the transmission of MVi + 2 or MVi + 2C to ani-
mals with the 129M/M genotype caused p-dCJD like
phenotype. These results suggest that p-dCJD is caused by
infection of V2 PrPSc and/or Mi PrPSc from sCJD patients
with VV2, MVi + 2, or MVi + 2C. Indeed, the incidence
rate of p-dCJD among total dura mater graft-associated
CJD is 32% [37], which is close to the sum total of the inci-
dence of VV2 (15%), MVi + 2 (8%), and MVi + 2C (3%) in
sCJD [5]. Since Mi PrPSc in individuals with the 129M/M
Kobayashi et al. Acta Neuropathologica Communications 2013, 1:74 Page 10 of 11
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might be a characteristic fingerprint of the infection of V2
PrPSc and/or Mi PrPSc to the 129M/M individuals.
Conclusions
The present study resolves the complicated pathogenesis
of MV2. The phenotypic heterogeneity of MV2 stems from
their different PrPSc origin(s).
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Additional file 1: Figure S1. Histotyping of the MV2 subgroups. (a-d)
Histopathological features of MV2K (a), MV2K + C (b), MV2C (c), or MM2C
(d). Hematoxylin and eosin stain and imunohistochemistry for PrP. Higher
magnification of kuru plaques (arrows) is shown in the insets. Scale bar:
100 μm. (e-h) Regional distribution of PrP plaques in MV2K (e), MV2K + C (f),
MV2C (g), or MM2C (h). Data are presented as mean ± SEM. FC, frontal cortex;
TC, temporal cortex; OC, occipital cortex; BG, basal ganglia (putamen); TH,
thalamus (dorsomedial nucleus); MB, midbrain; PO, pons; MO, medulla; CE,
cerebellum (granular cell layer).
Additional file 2: Figure S2. Immunohistochemical analysis of PrP in
the brains of MM2C-inoculated PrP-humanized mice. n, number of mice
positive for PrP accumulation in immunohistochemical analysis; n0, number
of inoculated mice. G, grey matter; W, white matter. Scale bar: 100 μm.
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